Program
Amlodipine
Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.
Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 570 open or running | phase 4since Aug 25, 2005 | Aug 25, 2005 | none ahead |
| Boehringer Ingelheimits history only | 220 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Viatrisits history only | 130 open or running | phase 4since Aug 31, 2005 | Aug 31, 2005 | none ahead |
| Hanmi Pharmaceuticalits history only | 110 open or running | phase 3since Jul 14, 2009 | Jul 14, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 80 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| HK inno.Nits history only | 50 open or running | phase 3since Feb 16, 2015 | Feb 10, 2014 | none ahead |
| Handokits history only | 40 open or running | phase 3since Jul 24, 2022 | Jul 21, 2020 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 9, 2009 | Feb 9, 2009 | none ahead |
| Yuhanits history only | 41 open or running | phase 4since Sep 4, 2023 | May 29, 2014 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Jan 8, 2016 | Feb 14, 2014 | none ahead |
| Daewoong Pharmaceuticalits history only | 30 open or running | phase 3since Dec 12, 2016 | Mar 4, 2013 | none ahead |
| IlDong Pharmaceuticalits history only | 30 open or running | phase 3since Apr 11, 2016 | Mar 31, 2016 | none ahead |
| Merckits history only | 30 open or running | phase 3since Feb 22, 2011 | Nov 10, 2008 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 1since Mar 9, 2015 | Mar 9, 2015 | none ahead |
| Menarini Groupits history only | 20 open or running | phase 4since Mar 4, 2022 | Mar 4, 2022 | none ahead |
| Midas Pharmaits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 1, 2009 | Jul 1, 2009 | none ahead |
| TSH Biopharmits history only | 20 open or running | phase 4since Jun 15, 2011 | Jun 15, 2011 | none ahead |
| Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratoriesits history only | 10 open or running | phase 1since Mar 10, 2016 | Mar 10, 2016 | none ahead |
| Celltrionits history only | 10 open or running | phase 3since Apr 27, 2026 | Apr 27, 2026 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jul 30, 2015 | Jul 30, 2015 | none ahead |
| Hyundai Pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| InVasc Therapeuticsits history only | 10 open or running | phase 4since Jan 5, 2011 | Jan 5, 2011 | none ahead |
| Kitov Pharmaceuticalsits history only | 10 open or running | phase 3since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Organonits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Mar 2, 2007 | Mar 2, 2007 | none ahead |
| Servierits history only | 10 open or running | phase 3since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Shanghai Haini Pharmaceuticalits history only | 10 open or running | phase 1since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| Shin Poong Pharmaceuticalits history only | 10 open or running | phase 2since Oct 24, 2016 | Oct 24, 2016 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Nov 17, 2016 | Nov 17, 2016 | none ahead |
| Zentiva, k.s.its history only | 11 open or running | phase 3since May 25, 2026 | May 25, 2026 | Dec 31, 2027phase 3 · NCT07618806 |
Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Feb 22, 2011.
- Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
- Jan 23, 2020Midas Pharma’s first study: phase 1 study in Healthy VolunteersNew to Midas PharmaMidas Pharma · NCT04245046 · 18 enrolled · Jordan
- Feb 7, 2020Phase 1 study in Healthy VolunteersMidas Pharma · NCT04262765 · 18 enrolled · Jordan
- Jul 21, 2020Handok’s first study: phase 2 study in Essential HypertensionNew to HandokHandok · NCT04488978 · 440 enrolled · Korea, Republic of
- Feb 25, 2022Servier’s first study: phase 3 study in Essential HypertensionNew to ServierServier · NCT05288400 · 150 enrolled · Russian Federation
- Mar 4, 2022Menarini Group’s first study: phase 4 study in HypertensionNew to Menarini GroupMenarini Group · NCT05279807 · 277 enrolled · Hungary
- Jul 24, 2022Phase 3 study in Essential HypertensionHandok · NCT05475665 · 157 enrolled · Korea, Republic of
- Aug 22, 2022Phase 4 study in HypertensionMenarini Group · NCT05513937 · 301 enrolled · Bulgaria
- Dec 14, 2022Phase 1 study in Healthy VolunteersHandok · NCT05663073 · 46 enrolled · Korea, Republic of
- Jan 8, 2023Phase 1 study in Healthy VolunteersHandok · NCT05688085 · 44 enrolled · Korea, Republic of
- Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
- Oct 15, 2024Hyundai Pharm’s first study: phase 3 study in HypertensionNew to Hyundai PharmHyundai Pharm · NCT06646354 · 125 planned · Korea, Republic of
- Apr 27, 2026Celltrion’s first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea
- May 25, 2026Zentiva, k.s.’s first study: phase 3 study in HypertensionNew to Zentiva, k.s.Zentiva, k.s. · NCT07618806 · 344 planned
Ahead
- Dec 31, 2027Primary completion: phase 3 study in HypertensionZentiva, k.s. · NCT07618806
TargetBeta
“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
| Gabapentinrule | Viatris | phase 4 | 49 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| Nifedipinerule | Bayer | phase 4 | 18 |
Studies
The newest 60 of 170 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07618806Hypertension | 3 | Not yet recruiting | Zentiva, k.s. | Dec 31, 2027 | 344 |
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | Hyundai Pharm | May 19, 2025 | 125 |
| NCT06041529Essential Hypertension · South Korea | 4 | Active, not recruiting | Yuhan | Feb 28, 2026 | 198 |
| NCT05688085Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Dec 29, 2022 | 44 |
| NCT05663073Healthy Volunteers · Korea, Republic of | 1 | Completed | Handok | Dec 15, 2022 | 46 |
| NCT05513937Hypertension · Bulgaria | 4 | Completed | Menarini Group | Nov 15, 2022 | 301 |
| NCT05475665Essential Hypertension · Korea, Republic of | 3 | Completed | Handok | Mar 30, 2023 | 157 |
| NCT05279807Hypertension · Hungary | 4 | Completed | Menarini Group | Apr 28, 2022 | 277 |
| NCT05288400Essential Hypertension · Russian Federation | 3 | Completed | Servier | Dec 18, 2018 | 150 |
| NCT04488978Essential Hypertension · Korea, Republic of | 2 | Completed | Handok | Nov 9, 2021 | 440 |
| NCT04262765Healthy Volunteers · Jordan | 1 | Completed | Midas Pharma | Mar 26, 2019 | 18 |
| NCT04245046Healthy Volunteers · Jordan | 1 | Completed | Midas Pharma | Feb 18, 2019 | 18 |
| NCT04161001Hypertension · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Nov 20, 2021 | 237 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04322266Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Feb 13, 2019 | 61 |
| NCT04081844Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Jun 28, 2018 | 31 |
| NCT03639480Hypertension · Korea, Republic of | 3 | UNKNOWN | HK inno.N | Oct 2018 | 180 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03536598Hypertension With Hyperlipidemia | 3 | Completed | HK inno.N | Sep 4, 2017 | 203 |
| NCT03009487Hypertension · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Apr 2018 | 265 |
| NCT02974439Bioequivalence · China | 1 | Completed | Shanghai Haini Pharmaceutical | Mar 21, 2017 | 60 |
| NCT02969265Hypertension · China | 3 | Withdrawn | Takeda | Jul 12, 2018 | 0 |
| NCT02944734Essential Hypertension · Korea, Republic of | 2 | Completed | Shin Poong Pharmaceutical | Dec 2015 | 392 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02899455Hypertension · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Jun 2016 | 146 |
| NCT02789475Hypertension · Korea, Republic of | 1 | UNKNOWN | Lotus Pharmaceutical | Jul 2016 | 38 |
| NCT02738632Essential Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Aug 2016 | 300 |
| NCT02739672Healthy · Korea, Republic of | 1 | Completed | IlDong Pharmaceutical | Apr 6, 2016 | 40 |
| NCT02707913Healthy | 1 | Completed | Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories | Aug 2016 | 17 |
| NCT02651870Hypertension · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Feb 25, 2016 | 135 |
| NCT02519010Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2011 | 36 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02368665Essential Hypertension · Korea, Republic of | 3 | Completed | HK inno.N | Nov 2015 | 180 |
| NCT02368652Essential Hypertension · Korea, Republic of | 3 | Completed | HK inno.N | Nov 2015 | 181 |
| NCT02387554Hypertension · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Oct 2014 | 33 |
| NCT02295046Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Oct 2011 | 80 |
| NCT02292069Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 90 |
| NCT02261064Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2009 | 32 |
| NCT02259829Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02259816Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 38 |
| NCT02233218Healthy Male Volunteer · Korea, Republic of | 1 | Completed | Yuhan | Oct 2014 | 60 |
| NCT02243319Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Dec 2014 | 24 |
| NCT02193308Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02183675Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 2014 | 36 |
| NCT02172040Hypertension · United Kingdom | 3 | Completed | Kitov Pharmaceuticals | Nov 19, 2015 | 152 |
| NCT02206165Essential Hypertension · Korea, Republic of | 2 | UNKNOWN | Chong Kun Dang Pharmaceutical | Apr 2015 | 456 |
| NCT02152969Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Aug 2014 | 66 |
| NCT02064556Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 2014 | 24 |
| NCT02062645Essential Hypertension · Turkey | 4 | Completed | Novartis | Sep 2015 | 115 |
| NCT02059616Essential Hypertension · Korea, Republic of | 2 | UNKNOWN | HK inno.N | Jun 2015 | 384 |
| NCT02058446Essential Hypertension · Taiwan | 4 | Completed | TSH Biopharm | Mar 2014 | 36 |
| NCT01911780Hypertension · Japan | 3 | Completed | Boehringer Ingelheim | Jan 2015 | 132 |
| NCT01806311Hypertension · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Aug 2013 | 36 |
| NCT01506011Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2007 | 50 |
| NCT01505998Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dr. Reddy's Laboratories | May 2007 | 49 |
| NCT01375322Hypertension · Taiwan | 4 | Completed | TSH Biopharm | Jun 2010 | 226 |
| NCT01302691Hypertension | 3 | Completed | Merck | Apr 1, 2012 | 327 |
How it is read
Names in the registry
- “Amlodipine”, 44 entries
- “amlodipine”, 14 entries
- “Amlodipine 5 mg”, 9 entries
- “Amlodipine 10 mg”, 6 entries
- “valsartan + amlodipine”, 5 entries
Conditions, from the studies’ own filings
- Hypertension, 119 studies
- Essential Hypertension, 32 studies
- Hyperlipidemias, 3 studies
- Kidney Diseases, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.